Jaguar Health (NASDAQ: JAGX) and Eiger Biopharmaceuticals (NASDAQ:EIGR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.
Risk & Volatility
Jaguar Health has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Eiger Biopharmaceuticals has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500.
Institutional & Insider Ownership
11.5% of Jaguar Health shares are owned by institutional investors. Comparatively, 53.0% of Eiger Biopharmaceuticals shares are owned by institutional investors. 6.9% of Jaguar Health shares are owned by insiders. Comparatively, 28.8% of Eiger Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Jaguar Health and Eiger Biopharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Jaguar Health||$140,000.00||97.32||-$14.73 million||($0.66)||-0.23|
|Eiger Biopharmaceuticals||N/A||N/A||-$47.08 million||($5.30)||-1.63|
Jaguar Health has higher revenue and earnings than Eiger Biopharmaceuticals. Eiger Biopharmaceuticals is trading at a lower price-to-earnings ratio than Jaguar Health, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current recommendations and price targets for Jaguar Health and Eiger Biopharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Jaguar Health currently has a consensus price target of $2.00, indicating a potential upside of 1,233.33%. Eiger Biopharmaceuticals has a consensus price target of $29.00, indicating a potential upside of 235.26%. Given Jaguar Health’s higher possible upside, equities analysts plainly believe Jaguar Health is more favorable than Eiger Biopharmaceuticals.
This table compares Jaguar Health and Eiger Biopharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Jaguar Health beats Eiger Biopharmaceuticals on 6 of the 11 factors compared between the two stocks.
About Jaguar Health
Jaguar Health, Inc., formerly Jaguar Animal Health, Inc., is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. Its other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.
About Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.